Selected research
Industry Research
Valsartan Industry Research Report 2026
Market perspective
The global Valsartan market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Valsartan is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Valsartan is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Valsartan is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Valsartan include Alembic Pharmaceuticals, Amneal Pharmaceuticals, Aurobindo Pharma, HETERO, Huaren Pharmaceutical, Jubilant Pharma, LG Life Sciences, Lupin and Macleods Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Valsartan market in terms of revenue (US$ million) and, where applicable, sales volume (K Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Valsartan Market by Company
Alembic Pharmaceuticals
Amneal Pharmaceuticals
Aurobindo Pharma
HETERO
Huaren Pharmaceutical
Jubilant Pharma
LG Life Sciences
Lupin
Macleods Pharmaceuticals
Square Pharmaceuticals
Torrent Pharmaceuticals
Unichem Laboratories
Mylan
Novartis
Sun Pharmaceutical
Teva
Zhejiang Huahai Pharmaceutical
Valsartan Segment by Type
80 mg Tablets
40 mg Tablets
320 mg Tablets
160 mg Tablets
Valsartan Segment by Application
Heart Failure
Heart Attack
Hypertension
Valsartan Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Valsartan market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Valsartan and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Valsartan.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Valsartan manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Valsartan by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Valsartan in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 80 mg Tablets
- 40 mg Tablets
- 320 mg Tablets
- 160 mg Tablets
Applications
- Heart Failure
- Heart Attack
- Hypertension
Companies covered
- Alembic Pharmaceuticals
- Amneal Pharmaceuticals
- Aurobindo Pharma
- HETERO
- Huaren Pharmaceutical
- Jubilant Pharma
- LG Life Sciences
- Lupin
- Macleods Pharmaceuticals
- Square Pharmaceuticals
- Torrent Pharmaceuticals
- Unichem Laboratories
- Mylan
- Novartis
- Sun Pharmaceutical
- Teva
- Zhejiang Huahai Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Valsartan Market Size (2021-2032)
- 2.2.2 Global Valsartan Sales (2021-2032)
- 2.2.3 Global Valsartan Market Average Price (2021-2032)
- 2.3 Valsartan by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 80 mg Tablets
- 2.3.3 40 mg Tablets
- 2.3.4 320 mg Tablets
- 2.3.5 160 mg Tablets
- 2.4 Valsartan by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Heart Failure
- 2.4.3 Heart Attack
- 2.4.4 Hypertension
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Valsartan Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Valsartan Sales (K Pcs) of Manufacturers (2021-2026)
- 3.3 Global Valsartan Revenue of Manufacturers (2021-2026)
- 3.4 Global Valsartan Average Price by Manufacturers (2021-2026)
- 3.5 Global Valsartan Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Valsartan, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Valsartan, Product Type & Application
- 3.8 Global Manufacturers of Valsartan, Established Date
- 3.9 Global Valsartan Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alembic Pharmaceuticals
- 4.1.1 Alembic Pharmaceuticals Company Information
- 4.1.2 Alembic Pharmaceuticals Business Overview
- 4.1.3 Alembic Pharmaceuticals Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alembic Pharmaceuticals Valsartan Product Portfolio
- 4.1.5 Alembic Pharmaceuticals Recent Developments
- 4.2 Amneal Pharmaceuticals
- 4.2.1 Amneal Pharmaceuticals Company Information
- 4.2.2 Amneal Pharmaceuticals Business Overview
- 4.2.3 Amneal Pharmaceuticals Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharmaceuticals Valsartan Product Portfolio
- 4.2.5 Amneal Pharmaceuticals Recent Developments
- 4.3 Aurobindo Pharma
- 4.3.1 Aurobindo Pharma Company Information
- 4.3.2 Aurobindo Pharma Business Overview
- 4.3.3 Aurobindo Pharma Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Aurobindo Pharma Valsartan Product Portfolio
- 4.3.5 Aurobindo Pharma Recent Developments
- 4.4 HETERO
- 4.4.1 HETERO Company Information
- 4.4.2 HETERO Business Overview
- 4.4.3 HETERO Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 HETERO Valsartan Product Portfolio
- 4.4.5 HETERO Recent Developments
- 4.5 Huaren Pharmaceutical
- 4.5.1 Huaren Pharmaceutical Company Information
- 4.5.2 Huaren Pharmaceutical Business Overview
- 4.5.3 Huaren Pharmaceutical Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Huaren Pharmaceutical Valsartan Product Portfolio
- 4.5.5 Huaren Pharmaceutical Recent Developments
- 4.6 Jubilant Pharma
- 4.6.1 Jubilant Pharma Company Information
- 4.6.2 Jubilant Pharma Business Overview
- 4.6.3 Jubilant Pharma Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jubilant Pharma Valsartan Product Portfolio
- 4.6.5 Jubilant Pharma Recent Developments
- 4.7 LG Life Sciences
- 4.7.1 LG Life Sciences Company Information
- 4.7.2 LG Life Sciences Business Overview
- 4.7.3 LG Life Sciences Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 LG Life Sciences Valsartan Product Portfolio
- 4.7.5 LG Life Sciences Recent Developments
- 4.8 Lupin
- 4.8.1 Lupin Company Information
- 4.8.2 Lupin Business Overview
- 4.8.3 Lupin Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lupin Valsartan Product Portfolio
- 4.8.5 Lupin Recent Developments
- 4.9 Macleods Pharmaceuticals
- 4.9.1 Macleods Pharmaceuticals Company Information
- 4.9.2 Macleods Pharmaceuticals Business Overview
- 4.9.3 Macleods Pharmaceuticals Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Macleods Pharmaceuticals Valsartan Product Portfolio
- 4.9.5 Macleods Pharmaceuticals Recent Developments
- 4.10 Square Pharmaceuticals
- 4.10.1 Square Pharmaceuticals Company Information
- 4.10.2 Square Pharmaceuticals Business Overview
- 4.10.3 Square Pharmaceuticals Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Square Pharmaceuticals Valsartan Product Portfolio
- 4.10.5 Square Pharmaceuticals Recent Developments
- 4.11 Torrent Pharmaceuticals
- 4.11.1 Torrent Pharmaceuticals Company Information
- 4.11.2 Torrent Pharmaceuticals Business Overview
- 4.11.3 Torrent Pharmaceuticals Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Torrent Pharmaceuticals Valsartan Product Portfolio
- 4.11.5 Torrent Pharmaceuticals Recent Developments
- 4.12 Unichem Laboratories
- 4.12.1 Unichem Laboratories Company Information
- 4.12.2 Unichem Laboratories Business Overview
- 4.12.3 Unichem Laboratories Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Unichem Laboratories Valsartan Product Portfolio
- 4.12.5 Unichem Laboratories Recent Developments
- 4.13 Mylan
- 4.13.1 Mylan Company Information
- 4.13.2 Mylan Business Overview
- 4.13.3 Mylan Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Mylan Valsartan Product Portfolio
- 4.13.5 Mylan Recent Developments
- 4.14 Novartis
- 4.14.1 Novartis Company Information
- 4.14.2 Novartis Business Overview
- 4.14.3 Novartis Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Novartis Valsartan Product Portfolio
- 4.14.5 Novartis Recent Developments
- 4.15 Sun Pharmaceutical
- 4.15.1 Sun Pharmaceutical Company Information
- 4.15.2 Sun Pharmaceutical Business Overview
- 4.15.3 Sun Pharmaceutical Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Sun Pharmaceutical Valsartan Product Portfolio
- 4.15.5 Sun Pharmaceutical Recent Developments
- 4.16 Teva
- 4.16.1 Teva Company Information
- 4.16.2 Teva Business Overview
- 4.16.3 Teva Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Teva Valsartan Product Portfolio
- 4.16.5 Teva Recent Developments
- 4.17 Zhejiang Huahai Pharmaceutical
- 4.17.1 Zhejiang Huahai Pharmaceutical Company Information
- 4.17.2 Zhejiang Huahai Pharmaceutical Business Overview
- 4.17.3 Zhejiang Huahai Pharmaceutical Valsartan Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Zhejiang Huahai Pharmaceutical Valsartan Product Portfolio
- 4.17.5 Zhejiang Huahai Pharmaceutical Recent Developments
5 Global Valsartan Market Scenario by Region
- 5.1 Global Valsartan Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Valsartan Sales by Region: 2021-2032
- 5.2.1 Global Valsartan Sales by Region: 2021-2026
- 5.2.2 Global Valsartan Sales by Region: 2027-2032
- 5.3 Global Valsartan Revenue by Region: 2021-2032
- 5.3.1 Global Valsartan Revenue by Region: 2021-2026
- 5.3.2 Global Valsartan Revenue by Region: 2027-2032
- 5.4 North America Valsartan Market Facts & Figures by Country
- 5.4.1 North America Valsartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Valsartan Sales by Country (2021-2032)
- 5.4.3 North America Valsartan Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Valsartan Market Facts & Figures by Country
- 5.5.1 Europe Valsartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Valsartan Sales by Country (2021-2032)
- 5.5.3 Europe Valsartan Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Valsartan Market Facts & Figures by Country
- 5.6.1 Asia Pacific Valsartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Valsartan Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Valsartan Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Valsartan Market Facts & Figures by Country
- 5.7.1 South America Valsartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Valsartan Sales by Country (2021-2032)
- 5.7.3 South America Valsartan Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Valsartan Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Valsartan Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Valsartan Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Valsartan Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Valsartan Sales by Type (2021-2032)
- 6.1.1 Global Valsartan Sales by Type (2021-2032) & (K Pcs)
- 6.1.2 Global Valsartan Sales Market Share by Type (2021-2032)
- 6.2 Global Valsartan Revenue by Type (2021-2032)
- 6.2.1 Global Valsartan Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Valsartan Revenue Market Share by Type (2021-2032)
- 6.3 Global Valsartan Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Valsartan Sales by Application (2021-2032)
- 7.1.1 Global Valsartan Sales by Application (2021-2032) & (K Pcs)
- 7.1.2 Global Valsartan Sales Market Share by Application (2021-2032)
- 7.2 Global Valsartan Revenue by Application (2021-2032)
- 7.2.1 Global Valsartan Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Valsartan Revenue Market Share by Application (2021-2032)
- 7.3 Global Valsartan Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Valsartan Value Chain Analysis
- 8.1.1 Valsartan Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Valsartan Production Mode & Process
- 8.2 Valsartan Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Valsartan Distributors
- 8.2.3 Valsartan Customers
9 Global Valsartan Analyzing Market Dynamics
- 9.1 Valsartan Industry Trends
- 9.2 Valsartan Industry Drivers
- 9.3 Valsartan Industry Opportunities and Challenges
- 9.4 Valsartan Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst